Fry Hannah 4

What Happened
Hannah Fry, Vice President & Controller of Protara Therapeutics (TARA), was granted a total of 64,500 restricted stock units (RSUs) on January 16, 2026. The grants are reported as 9,500 shares acquired at $0.00 and 55,000 shares reported as a derivative acquisition at $0.00, so no cash changed hands. These are awards (Form 4 code A) and represent contingent rights to receive common shares if and when the RSUs vest.

Key Details

• Transaction date: January 16, 2026; Filing date: January 21, 2026 (filed one business day after the typical 2‑business‑day Form 4 deadline).
• Grants: 9,500 RSUs @ $0.00 and 55,000 RSUs (derivative) @ $0.00; total 64,500 RSUs; reported value $0 at grant.
• Vesting (footnotes):
  • 9,500 RSUs: vest in three equal annual installments on the 1st, 2nd and 3rd anniversaries of Jan 16, 2026.
  • 55,000 RSUs: 25% vests on the one‑year anniversary of Jan 16, 2026, then 1/48th of the award vests monthly over the next three years.
• Shares owned following the transaction: not specified in the filing.
• No sale, tax‑withholding, 10b5‑1 plan, or cash exercise indicated — these are time‑based equity awards.

Context
RSUs are conditional awards that convert to actual shares only as they vest, so this grant does not represent immediate transferable stock. Such awards are common as compensation and retention tools for employees; they are not purchases (which some investors view as stronger insider bullish signals). The slightly late filing is administrative and should be noted when tracking insider timeliness.